SomnoMed (ASX: SOM) will soon begin a U.S. rollout of Zephyr Sleep Technologies MATRx system after the device received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
Importantly, the introduction of the device to the U.S. market, and eventually other markets, is likely to increase the number of referrals for SomnoMed’s oral sleep apnea appliance therapy, SomnoDent®.
MATRx is anticipated to improve patient care by enabling physicians to identify and characterise patients suitable for the SomnoDent® sleep apnea therapy.
The MATRx system will be used in sleep laboratories to identify patients that will be successful with oral appliance therapy while establishing the protrusive position of the lower mandible for effective therapy. “The MATRx system changes the way oral appliance therapy is prescribed, bringing the knowledge and expertise of both Sleep Physicians and Dentists into the therapy decision much earlier.
A MATRx study is performed in a sleep laboratory by a sleep technician in conjunction with a polysomnographic study. Using this new technology Sleep Physicians will, for the first time, be able to reliably predict the effectiveness of oral appliance therapy as a treatment for obstructive sleep apnea patients. This clears the way for Sleep Physicians to confidently prescribe oral appliance therapy in advance of patients being fitted with an oral appliance. MATRx also provides Sleep Dentists with an effective target protrusive position for the lower mandible.